Dr Jignesh gala retina specialist mumbai
Contact Us

Eylea Injection in Mumbai — Cost, Uses, Side Effects & the 2026 Price Revolution, Explained by a Retina Specialist

Leave a Comment / All / By

Eylea Injection in Mumbai — Cost, Uses, Side Effects & the 2026 Price Revolution, Explained by a Retina Specialist

Written & medically reviewed by Dr. Jignesh Gala, Vitreoretinal & Cataract Surgeon, Founder & Director — Crystal Clear Eye Clinic and Topax Eye Hospital, Mumbai. Prices & facts verified: 22 July 2026.

⚡ Quick answer: Eylea (aflibercept 2 mg) is a “VEGF-trap” eye injection that treats diabetic macular edema, wet AMD, retinal vein occlusion, diabetic retinopathy and myopic CNV. After Bayer’s April 2026 price cut (₹53,141 → ₹29,998 per vial), an Eylea injection in Mumbai now costs ₹25,000–38,000 all-inclusive — roughly half of what aggregator websites still quote. Available at Crystal Clear Eye Clinic, Andheri West, administered personally by Dr. Jignesh Gala (FRCS, LVPEI-trained retina surgeon) with cashless insurance. Call 077188 85245.

📢 THE 2026 EYLEA STORY no Mumbai website has told you yet: On 2 April 2026, Bayer cut Eylea’s India price by ~44% (₹53,141 → ₹29,998) after Zydus launched Anyra — India’s first aflibercept biosimilar — on 19 February 2026 (~₹25,000 indicative). A second biosimilar, Biocon’s Yesafili, is expected in H2 2026. And Eylea HD (8 mg) — despite what some sites advertise — is not yet approved or available in India as of July 2026. If any page still quotes ₹56,000–65,000 for Eylea, its information is over a year stale. This page is date-stamped and updated quarterly.

Your doctor has said the word “Eylea” — and Google gave you ten different prices, none dated, none explained. This is the page that fixes that: what Eylea actually is, the trial evidence (VIEW, VIVID/VISTA, Protocol T, CLARITY — all linked below), honest comparisons with Avastin, Accentrix, Vabysmo and the new biosimilars, real 2026 Mumbai pricing, insurance realities, and side-effect transparency from a surgeon who administers these injections every week.

📋 In this guide:

  1. What is Eylea & how does the “VEGF trap” work?
  2. 5 conditions Eylea treats — with the trial evidence
  3. Eylea vs Avastin vs Accentrix vs Vabysmo vs Anyra — honest comparison
  4. How many Eylea injections will you need?
  5. Injection day at our Andheri West clinic
  6. Side effects & safety — the honest numbers
  7. Eylea cost in Mumbai 2026 + Year-1 math
  8. Insurance & cashless
  9. Eylea HD (8 mg) — the India truth
  10. Why Dr. Jignesh Gala for your Eylea treatment
  11. Location, hours & suburbs
  12. FAQs
  13. Research library (120+ references)

1. What Is Eylea & How Does the “VEGF Trap” Work?

Eylea (aflibercept, made by Bayer/Regeneron) is a soluble decoy receptor — a specially engineered protein that acts like a sponge for VEGF. Where antibody-based drugs (Lucentis, Avastin) block VEGF-A alone, aflibercept’s “trap” binds VEGF-A, VEGF-B and PlGF (placental growth factor) — three leak-and-growth signals instead of one — with roughly 100× tighter binding than ranibizumab. Practically, that means stronger drying of a swollen retina and longer gaps between injections (typically 8–12 weeks vs 4 weeks). Its pivotal VIEW trials established it as equal-or-better to monthly ranibizumab for wet AMD with half the injections (Ophthalmology, 2012; 96-week VIEW results).

Dr. Jignesh Gala preparing Eylea aflibercept intravitreal injection beside OCT at Crystal Clear Eye Clinic Andheri West Mumbai

Every Eylea injection at our clinic is OCT-guided — we treat scan evidence, not calendar habit

2. The 5 Conditions Eylea Treats — With the Actual Trial Evidence

ConditionThe proofWhat it means for you
Diabetic macular edema (DME)VIVID/VISTA trials through 148 weeks (2014; 100-wk; 148-wk) + Protocol T (NEJM, 2015)The strongest DME evidence base of any drug — and Protocol T’s winner when starting vision is poor. Our DME care
Wet (neovascular) AMDVIEW 1 & 2 + extension studies (VIEW 1 extension; real-world meta-analysis)Equal vision gains to monthly ranibizumab with injections every 8+ weeks (ARMD treatment)
Retinal vein occlusion (BRVO/CRVO)VIBRANT (BRVO) + COPERNICUS/GALILEO (CRVO) (VIBRANT 52-wk; integrated analysis; LEAVO RCT)Rapid drying of vein-occlusion swelling, often within weeks
Diabetic retinopathy (severe NPDR/PDR)PANORAMA (JAMA Ophthalmol, 2021) + CLARITY vs PRP laser (Lancet, 2017; mechanism substudy)Reverses retinopathy severity levels on photos — matched PRP laser at 1 year. DR care
Myopic CNV (high minus power degeneration)MYRROR study (Ophthalmology, 2015; severity analysis)Often just 1–3 injections restore reading vision in young high myopes

3. Eylea vs Avastin vs Accentrix vs Vabysmo vs Anyra — the Honest 2026 Comparison

Eylea (aflibercept)Anyra (biosimilar aflibercept)Avastin (bevacizumab)Accentrix/Lucentis (ranibizumab)Vabysmo (faricimab)
TypeVEGF-trap fusion proteinSame molecule, biosimilar (Zydus, Feb 2026)Antibody (off-label)Antibody fragmentDual VEGF + Ang-2
Typical interval8–12 weeks8–12 weeks4–6 weeks4–6 weeks12–16 weeks
Best evidenceDME with poor vision (Protocol T), wet AMD, RVOPhase-3 equivalence data (SB15; INSIGHT DME trial)Cheapest proven (CATT, Cochrane)Two decades of trialsFewest injections/yr (YOSEMITE/RHINE)
Per injection (Mumbai, our clinic)₹25,000–38,000 (post-cut)₹18,000–28,000 (indicative)₹7,000–12,000₹15,000–30,000₹45,000–65,000
Year-1 estimate₹1.2–2.0 lakh₹0.9–1.6 lakh₹0.6–1.0 lakh₹1.0–2.4 lakh₹1.5–2.75 lakh

Our honest prescribing logic: DME with poorer starting vision → Eylea class wins (Protocol T proved it — 2-year results; 5-year extension). Good-vision DME or tight budget → Avastin/biosimilar ranibizumab is rational. Want Eylea-molecule benefits at lower cost → Anyra is 2026’s disruptor. Maximum interval between visits → Vabysmo. You get this analysis with your OCT in hand, not a sales pitch.

4. How Many Eylea Injections Will You Need?

  • Loading phase: 3–5 monthly injections to dry the retina (condition-dependent)
  • Maintenance: every 8 weeks fixed, or treat-and-extend — stretching by 2 weeks at a time when the OCT stays dry (real-world 2-year results confirm durability: Ophthalmol Ther, 2024)
  • Realistic Year-1: 6–8 injections for DME/wet AMD; fewer for myopic CNV (often 1–3 total)
  • Is it lifelong? Retinal vascular diseases are chronic — treatment relaxes over years but rarely “ends”; PANORAMA/VISTA data show early, regular treatment preserves the most vision (fellow-eye data, 2023)

5. Injection Day at Our Andheri West Clinic — 15 Minutes, Start to Finish

  1. Dilatation + same-day OCT review (we confirm the injection is truly needed)
  2. Numbing drops → povidone-iodine antisepsis → gentle lid speculum
  3. The injection: seconds, hair-thin 30-gauge needle — most patients say “that’s it?”
  4. Immediate pressure & circulation check; home in minutes with written aftercare
  5. OCT review at ~4 weeks to measure response and set your interval

Full step-by-step with photos: intravitreal injection — the complete patient guide.

Dr. Jignesh Gala examining patient before Eylea injection at Andheri West retina clinic Mumbai

Examination before every injection — the right drug, for the right eye, at the right interval

6. Side Effects & Safety — the Honest Numbers

Common & harmless (most patients): a red patch on the white of the eye (subconjunctival haemorrhage) for a few days, grittiness, a few floaters or bubbles for a day, mild pressure ache.

Uncommon: sustained eye-pressure rise (we check every visit), intraocular inflammation — a 2025 JAMA analysis tracked noninfectious inflammation after aflibercept (JAMA Ophthalmol, 2025; 2026 pharmacovigilance).

Rare but serious: endophthalmitis (infection inside the eye) at roughly 1 in 2,000–5,000 injections — minimised by our Betadine-first sterile protocol; retinal tear/detachment (<0.1%). Comprehensive RCT safety reviews across thousands of patients confirm Eylea’s systemic safety, including in diabetics (Ophthalmology, 2016; FAERS analysis, 2022).

🚨 After any injection, call 077188 85245 immediately if you develop: increasing pain, worsening redness, or rapidly dropping vision within 3 days. These are infection warning signs — caught early, treatable; ignored, dangerous.

7. Eylea Cost in Mumbai 2026 — Post-Cut Reality + Year-1 Math

ItemBefore Apr 2026Now (Jul 2026)
Eylea vial MRP₹53,141₹29,998 (−44%)
Eylea injection at our clinic (all-inclusive)₹35,000 – ₹50,000₹25,000 – ₹38,000
Anyra (biosimilar aflibercept) injectiondidn’t exist₹18,000 – ₹28,000 (indicative)
Year-1 total (Eylea, 6–7 injections)₹2.3 – ₹3.4 lakh₹1.2 – ₹2.0 lakh

Also budget: first-visit consultation ₹500–2,000 + OCT ₹1,500–3,000. Full cross-drug pricing: anti-VEGF injection cost in Mumbai — every drug compared. Why the cut matters: Eylea’s trial-grade efficacy at near-biosimilar pricing makes 2026 the first year the “best” choice and the “affordable” choice can be the same molecule for many patients.

8. Insurance & Cashless for Eylea

🏥 Direct cashless → Topax Eye Care (Topax Eye Hospital), Vile Parle East. Direct insurer tie-ups — pre-authorisation coordinated by our desk, treatment without upfront payment (per policy terms).

🏥 Third-party cashless (TPA) → Crystal Clear Eye Clinic, Andheri West. 25–30+ TPAs and GIPSA panels handled end-to-end.

Eylea-specific insurance notes: it is an approved, on-label drug for its indications (unlike off-label options), which smoothes claim approval; day-care categorisation, waiting periods for pre-existing diabetes, and per-injection sub-limits still decide your out-of-pocket — we verify all three before your first dose. Guides: cashless eye treatment in Mumbai · cashless guide by Dr. Gala. EMI plans available for multi-injection years.

Dr. Jignesh Gala and team at Topax Eye Hospital Vile Parle East — cashless Eylea injections Mumbai

Topax Eye Care, Vile Parle East — your direct-cashless facility for Eylea treatment

9. Eylea HD (Aflibercept 8 mg) — the India Truth

Some Mumbai pages advertise “Eylea HD” with prices. Here are the verifiable facts as of July 2026: aflibercept 8 mg is approved in the US (FDA, Aug 2023; RVO added Nov 2025), EU, UK, Japan, Korea and Australia, with PHOTON (DME) and PULSAR (wet AMD) trials showing equal results at 12–16 week intervals (PHOTON, Lancet 2024; real-world 8 mg switches: UK, 2025; Germany, 2025). But we found no CDSCO approval or launch for India — any “Eylea HD” offered locally is grey-market import without Indian regulatory oversight. Our commitment: the day it receives Indian approval, this page updates and genuine stock follows. Until then, we recommend approved molecules only.

10. Why Dr. Jignesh Gala for Your Eylea Treatment

Dr. Jignesh Gala — Eylea injection and retina specialist in Andheri West Mumbai

Dr. Jignesh Gala — FRCS (Ophth) Glasgow · MRCS Edinburgh · FICO London · DOMS (KEM) · MBBS (Grant Medical College)

Vitreoretinal & Cataract Surgeon | Founder & Director — Crystal Clear Eye Clinic & Topax Eye Hospital

  • Retina fellowship, L V Prasad Eye Institute · Former Asst. Professor, B.Y.L. Nair Hospital · Singapore experience
  • BMJ Case Reports peer reviewer — he reads Protocol T and PHOTON so your plan follows 2026 evidence (his research work)
  • Thousands of anti-VEGF injections across India & Singapore — every molecule from Avastin to Vabysmo
  • Honest drug selection: biosimilar-first when rational, Eylea when it wins, never brand-driven

Explore: best retina specialist in Mumbai · retina treatment in Andheri · eye specialist in Andheri · retina laser treatment · injection cost guide · eye injection explained · retina specialist profile · vitreoretinal treatment · diabetic eye care · surgical videos · advanced retinal care · retina surgery guide · vitrectomy surgery · macular edema treatment · sudden floaters check-up.

Dr. Jignesh Gala in operation theatre scrubs beside microscope — Eylea injection sterile protocol Andheri West

Sterile discipline is a habit here — every injection follows OT protocol

Operation theatre at Topax Eye Hospital — sterile Eylea injection protocol Mumbai

OT-grade sterility for a 30-second injection — that’s the standard here

11. Location, Hours & Suburbs We Serve

Crystal Clear Eye Clinic — Laram Centre CHS, A1-202, Swami Vivekanand Rd, above Sunil Jewellers, near NADCO Shopping Centre, Railway Colony, Andheri West, Mumbai, Maharashtra 400058 · Open daily, closes 9 pm · Phone/WhatsApp: 077188 85245

Dr. Jignesh Gala at Topax Eye Hospital — Eylea injection clinic near Lokhandwala Versova Andheri West

Dr. Gala at the Topax facility — one team, two locations

Minutes from Lokhandwala, Four Bungalows, Seven Bungalows, Versova, Yari Road, DN Nagar, Juhu, JVPD, Vile Parle, Oshiwara, Jogeshwari, Goregaon; Eylea patients visit from Bandra, Santacruz, Khar, Malad, Kandivali, Powai, Thane, Navi Mumbai and across the metro region.

मराठी सारांश: Eylea (aflibercept) हे डोळ्याचे VEGF-trap इंजेक्शन आहे — मधुमेह सूज, वयाची मॅक्युलर डिजेनेरेशन, नस दाबणे यांसाठी. एप्रिल 2026 पासून किंमत 44% ने घटून ₹29,998/व्हायल झाली; आमच्या क्लिनिकमध्ये ₹25,000–38,000 मध्ये इंजेक्शन. स्वस्त पर्याय: Anyra biosimilar. डॉ. जिग्नेश गाला (FRCS) स्वतः देतात. कॅशलेस उपलब्ध. फोन: 077188 85245.

हिंदी सारांश: Eylea (aflibercept) एक VEGF-trap आँख इंजेक्शन है — डायबिटिक सूजन, AMD, रेटिना नस दबने के लिए। अप्रैल 2026 से कीमत 44% घटकर ₹29,998/वायल; हमारे क्लिनिक में इंजेक्शन ₹25,000–38,000। सस्ता विकल्प: Anyra biosimilar। डॉ. जिग्नेश गाला (FRCS) स्वयं लगाते हैं। कैशलेस उपलब्ध। फोन: 077188 85245।

12. FAQs — Eylea Injection in Mumbai

What is Eylea injection used for?

Eylea (aflibercept 2 mg) treats diabetic macular edema, wet age-related macular degeneration, macular edema after retinal vein occlusion, diabetic retinopathy, and myopic choroidal neovascularization — all conditions where leaky retinal vessels threaten central vision.

What is the cost of Eylea injection in Mumbai in 2026?

After Bayer’s April 2026 price cut (₹53,141 → ₹29,998/vial), an all-inclusive Eylea injection at our Andheri West clinic costs ₹25,000–38,000. Biosimilar aflibercept (Anyra) is ₹18,000–28,000. Websites quoting ₹56,000–65,000 are using pre-cut prices.

Is Eylea better than Avastin?

For diabetic macular edema with poorer starting vision, yes — Protocol T proved aflibercept superior at 2 years. For milder disease, Avastin works comparably at far lower cost. We decide from your OCT and baseline vision, not from price lists alone.

Eylea vs Vabysmo — which should I choose?

Both are excellent. Vabysmo lasts longer (12–16 weeks) but costs more per dose; Eylea post-cut offers proven efficacy at roughly half the per-injection price. Budget-conscious with frequent-visit ability → Eylea. Fewest visits → Vabysmo.

How many Eylea injections will I need?

Usually 3–5 monthly loading doses, then every 8 weeks or treat-and-extend. DME/wet AMD patients average 6–8 injections in year one; myopic CNV often needs only 1–3 total.

Is the Eylea injection painful?

No — numbing drops make it a 30-second, pressure-only sensation for most patients. The anticipation is worse than the injection; most patients say “that’s it?” afterwards.

What are the side effects of Eylea?

Common: temporary red patch, grittiness, floaters for a day. Uncommon: eye-pressure rise, inflammation (monitored every visit). Rare: infection (about 1 in 2,000–5,000) — our sterile Betadine-first protocol minimises this, with a written warning-sign sheet after every injection.

Is Eylea covered by insurance in India?

Yes — it’s an approved on-label drug, which smoothes claims. Direct cashless via Topax Eye Care (Vile Parle East) and TPA cashless via Crystal Clear Eye Clinic (Andheri West). We verify waiting periods and sub-limits before you start.

Is Eylea HD (8 mg) available in Mumbai?

No — as of July 2026, aflibercept 8 mg has no CDSCO approval or launch in India. It’s available in the US/EU/UK/Japan. Beware of grey-market “Eylea HD” without Indian regulatory oversight. This page will update the moment genuine India stock exists.

What is Anyra, and is it as good as Eylea?

Anyra is Zydus’s biosimilar aflibercept — same molecule, made after the original’s patent window, launched in India in February 2026 at a lower price (~₹25,000 indicative). Biosimilar aflibercepts have phase-3 equivalence trials (SB15, INSIGHT). We offer it as a rational cost-saving alternative and explain the data honestly.

Can I switch from Avastin or Accentrix to Eylea mid-treatment?

Yes — switching up is common when response is incomplete; switching down when stable. Any switch is OCT-guided. Never “switch” by stopping — gaps cause permanent relapse.

Where can I get a genuine Eylea injection in Andheri West, Mumbai?

Crystal Clear Eye Clinic, Laram Centre, S.V. Road, Andheri West — genuine cold-chain-stored Eylea, administered personally by retina surgeon Dr. Jignesh Gala, open daily till 9 pm. Call 077188 85245.

Book Your Eylea Consultation — Same-Week Slots

Crystal Clear Eye Clinic — Laram Centre CHS, A1-202, Swami Vivekanand Rd, above Sunil Jewellers, near NADCO Shopping Centre, Railway Colony, Andheri West, Mumbai 400058 · Open daily, closes 9 pm

📞 Call 077188 85245 💬 WhatsApp Appointment

Direct cashless via Topax Eye Care · Third-party (TPA) cashless via Crystal Clear Eye Clinic

Disclaimer: Prices and availability verified 22 July 2026; drug pricing changes with manufacturer revisions. This page is educational, not a substitute for consultation. Genuine cold-chain medication used for every injection.

14. Research & Evidence Library — 120+ Verified References

💉 Aflibercept (Eylea) Clinical Evidence — PubMed (47 verified)

View 1 & View 2 — Wet Amd Pivotal Trials

  1. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology, 2012.
  2. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology, 2014.
  3. Extended (Every 12 Weeks or Longer) Dosing Interval With Intravitreal Aflibercept and Ranibizumab in Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of VIEW Trials. American journal of ophthalmology, 2019.
  4. Long-term Safety and Visual Outcome of Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration: VIEW 1 Extension Study. Ophthalmology. Retina, 2017.
  5. 2-Year Real-World Outcomes with Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration: Literature Review and Meta-analysis of Patient-Relevant Outcomes. Ophthalmology and therapy, 2021.

Vivid & Vista — Diabetic Macular Edema

  1. Intravitreal aflibercept for diabetic macular edema. Ophthalmology, 2014.
  2. Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies. Ophthalmology, 2015.
  3. Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies. Ophthalmology, 2016.
  4. Time to Resolution of Diabetic Macular Edema after Treatment with Intravitreal Aflibercept Injection or Laser in VISTA and VIVID. Ophthalmology. Retina, 2023.
  5. INCIDENCE OF NEW DIABETIC MACULAR EDEMA IN FELLOW EYES OF PATIENTS IN THE VISTA AND VIVID STUDIES. Retina (Philadelphia, Pa.), 2023.

Protocol T — Aflibercept Vs Bevacizumab Vs Ranibizumab

  1. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. The New England journal of medicine, 2015.
  2. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. Ophthalmology, 2016.
  3. Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study). Ophthalmology, 2020.
  4. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice. JAMA ophthalmology, 2016.
  5. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab. JAMA ophthalmology, 2017.
  6. Cost-effectiveness of ranibizumab and aflibercept to treat diabetic macular edema from a US perspective: analysis of 2-year Protocol T data. Journal of medical economics, 2020.

Rvo — Galileo / Copernicus / Vibrant

  1. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology, 2015.
  2. Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study. Ophthalmology, 2016.
  3. Integrated results from the COPERNICUS and GALILEO studies. Clinical ophthalmology (Auckland, N.Z.), 2017.
  4. Impact of Baseline Retinal Nonperfusion and Macular Retinal Capillary Nonperfusion on Outcomes in the COPERNICUS and GALILEO Studies. Ophthalmology. Retina, 2019.
  5. Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT. Health technology assessment (Winchester, England), 2021.

Myrror — Myopic Cnv

  1. Intravitreal Aflibercept Injection in Patients with Myopic Choroidal Neovascularization: The MYRROR Study. Ophthalmology, 2015.
  2. Influence of myopic macular degeneration severity on treatment outcomes with intravitreal aflibercept in the MYRROR study. Acta ophthalmologica, 2019.

Ziv-Aflibercept

  1. INTRAVITREAL ZIV-AFLIBERCEPT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: 52-Week Results. Retina (Philadelphia, Pa.), 2019.
  2. Intravitreal ziv-aflibercept in diabetic vitreous hemorrhage. International journal of retina and vitreous, 2020.
  3. Intravitreal Ziv-Aflibercept in Patients With Diabetic Macular Edema Refractory to Intravitreal Bevacizumab. Ophthalmic surgery, lasers & imaging retina, 2020.
  4. Intravitreal Ziv-Aflibercept: A Comprehensive Review. Seminars in ophthalmology, 2019.
  5. Safety of 5914 intravitreal ziv-aflibercept injections. The British journal of ophthalmology, 2019.

Aflibercept Biosimilars (Sb15, Myl-1701P, Sdz-Afl, Abp 938, Ql1207)

  1. Efficacy and Safety of the Aflibercept Biosimilar SB15 in Neovascular Age-Related Macular Degeneration: A Phase 3 Randomized Clinical Trial. JAMA ophthalmology, 2023.
  2. Biosimilar SB15 versus reference aflibercept in neovascular age-related macular degeneration: 1-year and switching results of a phase 3 clinical trial. BMJ open ophthalmology, 2023.
  3. Aflibercept Biosimilar MYL-1701P vs Reference Aflibercept in Diabetic Macular Edema: The INSIGHT Randomized Clinical Trial. JAMA ophthalmology, 2024.
  4. EFFICACY AND SAFETY OF THE PROPOSED BIOSIMILAR AFLIBERCEPT, SDZ-AFL, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: 52-Week Results From the Phase 3 Mylight Study. Retina (Philadelphia, Pa.), 2024.
  5. Randomized Trial of Biosimilar ABP 938 Compared with Reference Aflibercept in Adults with Neovascular Age-Related Macular Degeneration. Ophthalmology. Retina, 2026.
  6. Efficacy and Safety of Biosimilar QL1207 vs. the Reference Aflibercept for Patients with Neovascular Age-Related Macular Degeneration: A Randomized Phase 3 Trial. Ophthalmology and therapy, 2024.

Treat-And-Extend & Real World

  1. Two-Year Real-World Results for Aflibercept Using the Treat-and-Extend Regimen in Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy. Ophthalmology and therapy, 2024.
  2. Impact of COVID-19 on a real-world treat-and-extend regimen with aflibercept for neovascular age-related macular degeneration. Canadian journal of ophthalmology, 2025.
  3. Early Real-World Outcomes of Switching to 8 mg Aflibercept for Neovascular Age-Related Macular Degeneration in the United Kingdom. Life (Basel, Switzerland), 2025.
  4. Early Outcome of Aflibercept 8 mg for Neovascular AMD in the Real-world Setting. Klinische Monatsblatter fur Augenheilkunde, 2025.

Clarity & Panorama — Diabetic Retinopathy

  1. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a phase 2b non-inferiority trial. Lancet (London, England), 2017.
  2. Clinical efficacy and mechanistic evaluation of aflibercept for proliferative diabetic retinopathy (CLARITY): study protocol. BMJ open, 2015.
  3. Mechanistic Evaluation of Panretinal Photocoagulation Versus Aflibercept in Proliferative Diabetic Retinopathy: CLARITY Substudy. Investigative ophthalmology & visual science, 2018.
  4. Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial. JAMA ophthalmology, 2021.
  5. Consistency of Treatment Effect with Aflibercept by Baseline Factors in PANORAMA. Ophthalmology. Retina, 2023.

Safety

  1. Comprehensive Review of Ocular and Systemic Safety Events with Intravitreal Aflibercept Injection in Randomized Controlled Trials. Ophthalmology, 2016.
  2. Ocular adverse events associated with anti-VEGF therapy: A pharmacovigilance study of the FDA adverse event reporting system (FAERS). Frontiers in pharmacology, 2022.
  3. Noninfectious Intraocular Inflammation After Intravitreal Aflibercept. JAMA ophthalmology, 2025.
  4. Ocular adverse events associated with aflibercept and faricimab: a population-based pharmacovigilance study. Canadian journal of ophthalmology, 2026.

🏛️ Global Authorities & Trial Registries (40 verified)

AAO (aao.org) — 7 links

EyeWiki (eyewiki.org) — 5 links

  • EyeWiki: Intravitreal Injections — Physician-reviewed reference on injection technique, indications, and complications.
  • EyeWiki: Aflibercept — Drug monograph on Eylea: mechanism, dosing, trial evidence.
  • EyeWiki: Ranibizumab — Drug monograph on Lucentis: mechanism, indications, key trials.
  • EyeWiki: Faricimab — Drug monograph on Vabysmo, the dual VEGF/Ang-2 inhibitor.
  • EyeWiki: Endophthalmitis — Reference on the most serious injection complication: signs, management, prognosis.

ASRS (asrs.org) — 5 links

Retinal Physician (retinalphysician.com) — 3 links

Landmark journal article pages (DOI-resolving) — 6 links

ClinicalTrials.gov (all confirmed via official v2 API) — 10 links

NEI (nei.nih.gov) — 2 links

MedlinePlus — 2 links

📚 Related Retina Evidence — PubMed

Faricimab (Vabysmo) Trials

  1. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet (London, England), 2022.
  2. TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2. Ophthalmology, 2024.
  3. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet (London, England), 2022.
  4. Four-Year Outcomes of Faricimab in Diabetic Macular Edema: Results from the RHONE-X Extension Trial. Ophthalmology, 2026.
  5. Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial. Ophthalmology, 2019.
  6. Efficacy and Safety of Faricimab for Macular Edema due to Retinal Vein Occlusion: 24-Week Results from the BALATON and COMINO Trials. Ophthalmology, 2024.
  7. Anatomic Outcomes with Faricimab vs Aflibercept in Head-to-Head Dosing Phase of the TENAYA/LUCERNE Trials in Neovascular Age-related Macular Degeneration. Ophthalmology, 2025.
  8. Faricimab Treat-and-Extend Dosing for Macular Edema Due to Retinal Vein Occlusion: 72-Week Results from the BALATON and COMINO Trials. Ophthalmology. Retina, 2025.
  9. Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2024.

Aflibercept 8 Mg (Photon / Pulsar)

  1. Aflibercept 8 mg versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials. Ophthalmology and therapy, 2025.
  2. A Matching-Adjusted Comparison of Faricimab and Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema. Ophthalmic research, 2026.
  3. Economic Benefit of Aflibercept 8 mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US. Ophthalmology and therapy, 2025.
  4. Intraocular Pressure Outcomes with Intravitreal Aflibercept 8 mg: A 96-Week Pooled Analysis from PULSAR and PHOTON. Ophthalmology and therapy, 2026.
  5. A Response to: Letter to the Editor Regarding "Aflibercept 8 mg Versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials". Ophthalmology and therapy, 2026.
  6. Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial. JAMA ophthalmology, 2023.
  7. High-Dose 8 mg Aflibercept for Neovascular Age-Related Macular Degeneration: Who Is Being Treated with This New Agent? Life (Basel, Switzerland), 2025.
  8. Aflibercept high-dose (8mg) related intraocular inflammation (IOI) – a case series. BMC ophthalmology, 2024.
  9. Clinical Outcomes of High-Dose Aflibercept 8 mg in Polypoidal Choroidal Vasculopathy: A Systematic Review and Meta-Analysis. Cureus, 2026.
  10. Initial Functional and Anatomical Outcomes of High-dose Aflibercept 8 mg in Exudative Neovascular Age-related Macular Degeneration. Ophthalmology. Retina, 2025.

Treat-And-Extend Anti-Vegf

  1. Treat-and-extend dosing of intravitreal anti-VEGF agents in neovascular age-related macular degeneration: a meta-analysis. Eye (London, England), 2023.
  2. TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: A Literature Review and Consensus Recommendations. Retina (Philadelphia, Pa.), 2015.
  3. Vitrectomy as an Adjunct to Treat-and-Extend Anti-VEGF Injections for Diabetic Macular Edema: The Vitrectomy in Diabetic Macular Oedema (VIDEO) Randomized Clinical Trial. JAMA ophthalmology, 2024.
  4. Efficacy, safety, and treatment burden of treat-and-extend versus alternative anti-VEGF regimens for nAMD: a systematic review and meta-analysis. Eye (London, England), 2023.
  5. Treat and Extend Treatment Interval Patterns with Anti-VEGF Therapy in nAMD Patients. Vision (Basel, Switzerland), 2019.
  6. A Systematic Review of the Treat and Extend Treatment Regimen with Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration. Ophthalmology and therapy, 2017.
  7. The Role of Intravitreal Corticosteroids in the Treatment of DME: Predictive OCT Biomarkers. International journal of molecular sciences, 2022.
  8. Progress and Challenges of Anti-VEGF Agents and Their Sustained-Release Strategies for Retinal Angiogenesis. Drug design, development and therapy, 2022.
  9. Treat and Extend Anti-VEGF Treatment Regimens for Neovascular Age-Related Macular Degeneration: To Stop or Not to Stop? Clinical & experimental ophthalmology, 2025.
  10. Treat-and-extend regimens of anti-vascular endothelial growth factor therapy for retinal vein occlusions: a systematic review and meta-analysis. Acta ophthalmologica, 2022.

Intravitreal Injection Real-World India

  1. Real-World Evidence in the Management of Diabetic Macular Edema with Intravitreal Anti-VEGFs in Asia: A Systematic Literature Review. Clinical ophthalmology (Auckland, N.Z.), 2022.
  2. Real-World Safety Outcomes of Intravitreal Ranibizumab Biosimilar (Razumab) Therapy for Chorioretinal Diseases. Ophthalmology and therapy, 2021.
  3. REal-world treatment outcomes after delayed intRavitreal therapy in center-involving diabetic macular edema – RETORT study. International journal of retina and vitreous, 2023.
  4. "Real world outcomes of intravitreal brolucizumab for persistent diabetic macular edema". International journal of retina and vitreous, 2025.
  5. Real-world experience of brolucizumab in nAMD. Indian journal of ophthalmology, 2024.
  6. Real-world outcomes of intravitreal anti-vascular endothelial growth factor monotherapy in proliferative type 2 macular telangiectasia. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2021.
  7. Ranizurel safety evaluation in real-world -(RaSER) study. American journal of ophthalmology case reports, 2022.
  8. Initial experience with brolucizumab for neovascular age-related macular degeneration (nAMD) in India – Multicentric, real-world study. Indian journal of ophthalmology, 2024.
  9. Real-world evidence of safety profile of intravitreal bevacizumab (Avastin) in an Indian scenario. Indian journal of ophthalmology, 2017.
  10. Factors determining compliance with recommended intravitreal injections for retinal diseases among out-of-pocket, fully subsidized (non-paying), and insured patients: Real-world evidence from India. Indian journal of ophthalmology, 2025.
author avatar
drjigneshgala@gmail.com
See Full Bio

Leave a Comment

Your email address will not be published. Required fields are marked *